Gsk (GSK) Free Cash Flow (2009 - 2026)

Gsk (GSK) has 18 years of Free Cash Flow data on file, last reported at $5.9 billion in Q3 2026.

• For the quarter ending Q3 2026, Free Cash Flow changed N/A year-over-year to $5.9 billion; the trailing twelve-month figure through Sep 2026 stood at $16.8 billion (changed N/A YoY), and the FY2025 full-year result was $12.1 billion, up 18.92% from the prior year.
• Free Cash Flow was $5.9 billion for Q3 2026 at Gsk, up from $4.0 billion in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $5.9 billion in Q3 2026 to a low of $347.6 million in Q1 2023.
• A 5-year average of $2.9 billion and a median of $2.5 billion in 2025 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow sank 89.2% in 2023 and surged 340.07% in 2024, its largest moves.
• Gsk's Free Cash Flow stood at $5.3 billion in 2022, then sank by 56.02% to $2.3 billion in 2023, then jumped by 57.61% to $3.7 billion in 2024, then jumped by 37.29% to $5.1 billion in 2025, then increased by 15.92% to $5.9 billion in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were $5.9 billion in Q3 2026, $4.0 billion in Q2 2026, and $1.8 billion in Q1 2026.